Immobility-reducing Effects of Ketamine during the Forced Swim Test on 5-HT1A Receptor Activity in the Medial Prefrontal Cortex in an Intractable Depression Model.
5-HT1A receptor
adrenocorticotropic hormone
forced swim test
ketamine
medial prefrontal cortex
Journal
Acta medica Okayama
ISSN: 0386-300X
Titre abrégé: Acta Med Okayama
Pays: Japan
ID NLM: 0417611
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
entrez:
27
8
2020
pubmed:
28
8
2020
medline:
8
6
2021
Statut:
ppublish
Résumé
Ketamine has been clinically proven to ameliorate depression, including treatment-resistant depression. The detailed mechanism of action of ketamine in treatment-resistant depression remains unclear. We examined the effects of ketamine on the immobility times of adrenocorticotropic hormone (ACTH)-treated rats during the forced swim test, and we explored the mechanism by which ketamine acts in this model. We investigated the neuroanatomical site of action by microinjecting ketamine into the medial prefrontal cortex of rats. A significant reduction of the rats' immobility during the forced swim test was observed after the intraperitoneal injection of ketamine in both saline- and ACTH-treated rats. The microinjection of ketamine into the medial prefrontal cortex also decreased immobility during the forced swim test in both saline- and ACTH-treated rats. The immobility-decreasing effect of intraperitoneally injected ketamine was blocked by administering WAY100635, a 5-HT1A receptor antagonist, into the medial prefrontal cortex. These findings contribute to the evidence that ketamine can be useful against treatment-resistant depressive conditions. The immobility-reducing effects of ketamine might be mediated by 5-HT1A receptor activity in the medial prefrontal cortex.
Substances chimiques
Receptors, Serotonin
0
Ketamine
690G0D6V8H
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
301-306Déclaration de conflit d'intérêts
No potential conflict of interest relevant to this article was reported.
Références
Carroll BJ, Curtis GC and Mendels J: Neuroendocrine regulation in depression. II. Discrimination of depressed from nondepressed patients. Arch Gen Psychiatry (1976) 33: 1051-1058.
Kitamura Y, Araki H and Gomita Y: Influence of ACTH on the effects of imipramine, desipramine and lithium on duration of immobility of rats in the forced swim test. Pharmacol Biochem Behav (2002) 71: 63-69.
Walker AJ, Foley BM, Sutor SL, McGillivray JA, Frye MA and Tye SJ: Peripheral proinflammatory markers associated with ketamine response in a preclinical model of antidepressant-resistance. Behav Brain Res (2015) 293: 198-202.
Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS and Krystal JH: Antidepressant effects of ketamine in depressed patients. Biol Psychiatry (2000) 47: 351-354.
Aan Het Rot M, Zarate CA, Jr., Charney DS and Mathew SJ: Ketamine for depression: where do we go from here? Biol Psychiatry (2012) 72: 537-547.
Zarate CA, Jr., Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS and Manji HK: A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry (2006) 63: 856-864.
Fukumoto K, Toki H, Iijima M, Hashihayata T, Yamaguchi JI, Hashimoto K and Chaki S: Antidepressant Potential of (R)-Ketamine in Rodent Models: Comparison with (S)-Ketamine. J Pharmacol Exp Ther (2017) 361: 9-16.
Viana GSB, Xavier CC, do Vale EM, Lopes MJP, Alves VJ, Costa RO and Neves KRT: The monoaminergic pathways and inhibition of monoamine transporters interfere with the antidepressivelike behavior of ketamine. IBRO Rep (2018) 4: 7-13.
Richardson-Jones JW, Craige CP, Guiard BP, Stephen A, Metzger KL, Kung HF, Gardier AM, Dranovsky A, David DJ, Beck SG, Hen R and Leonardo ED: 5-HT1A autoreceptor levels determine vulnerability to stress and response to antidepressants. Neuron (2010) 65: 40-52.
Kishi T, Meltzer HY, Matsuda Y and Iwata N: Azapirone 5-HT1A receptor partial agonist treatment for major depressive disorder: systematic review and meta-analysis. Psychol Med (2014) 44: 2255-2269.
Kitamura Y, Araki H, Shibata K, Gomita Y and Tanizaki Y: 5-HT(1A) receptor full agonist, 8-OH-DPAT, exerts antidepressant-like effects in the forced swim test in ACTH-treated rats. Eur J Pharmacol (2003) 481: 75-77.
Fukumoto K, Iijima M, Funakoshi T and Chaki S: Role of 5-HT1A Receptor Stimulation in the Medial Prefrontal Cortex in the Sustained Antidepressant Effects of Ketamine. Int J Neuropsychopharmacol (2018) 21: 371-381.
Fukumoto K, Iijima M and Chaki S: Serotonin-1A receptor stimulation mediates effects of a metabotropic glutamate 2/3 receptor antagonist, 2S-2-amino-2-(1S,2S-2-carboxycycloprop-1-yl)-3-(xanth-9-yl)propanoic acid (LY341495), and an N-methyl-D-aspartate receptor antagonist, ketamine, in the novelty-suppressed feeding test. Psychopharmacology (Berl) (2014) 231: 2291-2298.
Inoue T, Koyama T and Yamashita I: Effect of conditioned fear stress on serotonin metabolism in the rat brain. Pharmacol Biochem Behav (1993) 44: 371-374.
Nishitani N, Nagayasu K, Asaoka N, Yamashiro M, Shirakawa H, Nakagawa T and Kaneko S: Raphe AMPA receptors and nicotinic acetylcholine receptors mediate ketamine-induced serotonin release in the rat prefrontal cortex. Int J Neuropsychopharmacol (2014) 17: 1321-1326.
Pham TH, Mendez-David I, Defaix C, Guiard BP, Tritschler L, David DJ and Gardier AM: Ketamine treatment involves medial prefrontal cortex serotonin to induce a rapid antidepressant-like activity in BALB/cJ mice. Neuropharmacology (2017) 112: 198-209.
Fukumoto K, Iijima M and Chaki S: The Antidepressant Effects of an mGlu2/3 Receptor Antagonist and Ketamine Require AMPA Receptor Stimulation in the mPFC and Subsequent Activation of the 5-HT Neurons in the DRN. Neuropsychopharmacology (2016) 41: 1046-1056.
Porsolt RD, Anton G, Blavet N and Jalfre M: Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol (1978) 47: 379-391.
Fukumoto K, Iijima M, Funakoshi T and Chaki S: 5-HT1A receptor stimulation in the medial prefrontal cortex mediates the antidepressant effects of mGlu2/3 receptor antagonist in mice. Neuropharmacology (2018) 137: 96-103.
Chaki S, Ago Y, Palucha-Paniewiera A, Matrisciano F and Pilc A: mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants. Neuropharmacology (2013) 66: 40-52.
Dong C, Zhang JC, Yao W, Ren Q, Ma M, Yang C, Chaki S and Hashimoto K: Rapid and Sustained Antidepressant Action of the mGlu2/3 Receptor Antagonist MGS0039 in the Social Defeat Stress Model: Comparison with Ketamine. Int J europsychopharmacol (2017) 20: 228-236.
Dwyer JM, Lepack AE and Duman RS: mGluR2/3 blockade produces rapid and long-lasting reversal of anhedonia caused by chronic stress exposure. J Mol Psychiatry (2013) 1: 15.
Ago Y, Yano K, Araki R, Hiramatsu N, Kita Y, Kawasaki T, Onoe H, Chaki S, Nakazato A, Hashimoto H, Baba A, Takuma K and Matsuda T: Metabotropic glutamate 2/3 receptor antagonists improve behavioral and prefrontal dopaminergic alterations in the chronic corticosterone-induced depression model in mice. Neuropharmacology (2013) 65: 29-38.